Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Kallisto demonstrates major new version of BYOSYS solution at Orthopädie + Reha-Technik show

SensAble Technologies, Inc®, a leading provider of 3D modeling solutions and haptic devices, announced that its customer, Kallisto, a provider of 3D technologies as well as rapid prototyping and manufacturing solutions to the orthotics and prosthetics industry, is showcasing a major new version of its BYOSYS® solution at Europe's leading industry event, the Orthopädie + Reha-Technik show, which opened in Leipzig, Germany today.

12 May 2010

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

A new Mayo Clinic study has found that Gamma Knife™ stereotactic radiosurgery is a safe and effective option for selected children with arteriovenous malformations. This study was presented at the American Association of Neurological Surgeons Annual Meeting in Philadelphia last week.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Adult patients with sickle cell disease may develop cognitive problems: Study

Sickle cell disease may affect brain function in adults who have few or mild complications of the inherited blood disease, according to results of the first study to examine cognitive functioning in adults with sickle cell disease.

12 May 2010

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Chocolate, coffee and red wine may not benefit the heart: Study

Heart Foundation revealed in a recent review of over 100 studies over the last decade that claims of chocolates, red wine and coffee that are supposedly loaded with antioxidants that do good to the heart are unreliable.

11 May 2010

LifeWatch Services to launch remote iPad ECG report TeleViewer application

LifeWatch Services, Inc., a subsidiary of LifeWatch AG, will announce the launch of their remote ECG report TeleViewer™ application for the Apple iPad. The iPad application integrates with and enhances the advanced reporting and workflow management capabilities present in their web based applications for all product offerings.

11 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Duchenne muscular dystrophy research at the University of Florida got a major boost with the award of $7.5 million in National Institutes of Health funding to study the use of magnetic resonance imaging in determining the natural progression of the disease.

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.

7 May 2010

Two-day symposium on molecular neuroimaging

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.

7 May 2010

Inadvertent reprogramming of genes in peripheral nervous system may cause chronic pain

Chronic pain severely limits patients' quality of life and is among the cost drivers in U.S. health care. Patients can suffer pain without an apparent cause and often fail to respond to available treatments. Mayo Clinic researchers and collaborators now report that chronic pain may be caused by the inadvertent reprogramming of more than 2,000 genes in the peripheral nervous system. The research findings appear in the current issue of the journal Genome Research.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

Stroke News and Research

Further Reading

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

Kallisto demonstrates major new version of BYOSYS solution at Orthopädie + Reha-Technik show

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Adult patients with sickle cell disease may develop cognitive problems: Study

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Chocolate, coffee and red wine may not benefit the heart: Study

LifeWatch Services to launch remote iPad ECG report TeleViewer application

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

Two-day symposium on molecular neuroimaging

Inadvertent reprogramming of genes in peripheral nervous system may cause chronic pain

Natazia tablets receive FDA approval for prevention of pregnancy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News